Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VLP-Polio Vaccine in Healthy Adults
NCT06101173Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of vlp-polio in poliomyelitis (6 arms), sponsored by CanSino Biologics Inc. Primary endpoint: Occurrence of solicited adverse reactions. Started Jan 2024; status: completed.
02
Drugs
vlp-polio
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT06101173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101173.